24310-36-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE is used as an intermediate for the preparation of nonpeptide vasopressin V2 receptor antagonists, specifically tetrahydro-1H-benzazepines. These antagonists are important in the development of drugs targeting conditions related to the vasopressin system, such as diabetes insipidus and certain types of hypertension.
1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE is also used to synthesize 4''-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-phenylbenzanilide derivatives. These derivatives are non-peptide arginine vasopressin antagonists that target both V1A and V2 receptors, which can be utilized in the treatment of various conditions, including heart failure and hyponatremia.

InChI:InChI=1/C17H17NO3S/c1-13-8-10-14(11-9-13)22(20,21)18-12-4-7-17(19)15-5-2-3-6-16(15)18/h2-3,5-6,8-11H,4,7,12H2,1H3

Upstream product

• 881417-10-3 N-{2-[1-tert-butyldimethylsilyloxy-4-(tetrahydropyran-2-yloxy)butyl]phenyl}-p-toluenesulfonamide 
• 881417-11-4 N-{2-[1-hydroxy-4-(tetrahydropyran-2-yloxy)butyl]phenyl}-p-toluenesulfonamide 
• 881417-12-5 N-{2-[1-oxo-4-(tetrahydropyran-2-yloxy)butyl]phenyl}-p-toluenesulfonamide 
• 881417-01-2 2-[1-tert-butyldimethylsilyloxy-4-(tetrahydropyran-2-yloxy)butyl]nitrobenzene 
• 881417-09-0 2-(1-tert-butyldimethylsilyloxy)-4-(tetrahydropyran-2-yloxybutyl)aniline 
• 881417-00-1 2-(1-tert-butyldimethylsilyloxy-4-hydroxybutyl)nitrobenzene 
• 881416-99-5 2-(1-tert-butyldimethylsilylbut-3-enyl)nitrobenzene 
• 881417-31-8 N-[2-(4-hydroxy-1-oxobutyl)phenyl]-p-toluenesulfonamide 
• 1127-74-8 1,2,3,4-tetrahydro-5H-benzo[b] azepin-5-one 
• 98-59-9 p-toluenesulfonyl chloride 
• 100627-39-2 N-(3-ethoxycarbonyl-propyl)-N-(toluene-4-sulfonyl)-anthranilic acid methyl ester 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 50998-74-8 methyl N-tosylanthranilate 
• 103151-64-0 4-[N-(toluene-4-sulfonyl)-anilino]-butyric acid 

Downstream Products

• 3749-15-3 1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-spiro[benzo[b]azepine-5,2'-[1,3]dioxolane] 
• 54620-86-9 1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-spiro[benzo[b]azepine-5,2'-[1,3]dioxane] 
• 130719-75-4 5-(ethoxycarbonylmethyl)-5-hydroxy-N-tosyl-2,3,4,5-tetrahydrobenzazepine 
• 153894-24-7 5-chloro-1-tosyl-2,3-dihydro-1H-benzo[b]azepine-4-carbaldehyde 
• 211573-42-1 4-benzylidene-1,2,3,4-tetrahydro-1-tosyl[2]benzazepin-5[H]one 
• 19673-33-7 5-hydroxy-1-(p-toluenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 168163-93-7 4-fluoro-1-(p-toluenesulfonyl)-1,2,3,4-tetrahydro-5H-1-benzoazepin-5-one 
• 153894-35-0 6-(4-methylphenyl sulfonyl)-5,6-dihydro-4H-benzo[3,4]cyclohepta[d][1,3]thiazol-2-amine 
• 130719-76-5 ethyl {1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate 
• 29489-04-1 4-bromo-1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one 
• 876048-15-6 2-[1-(4-methylphenylsulphonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yliden] malononitrile 
• 876048-17-8 2-amino-6-(4-methylphenylsulphonyl)-5,6-dihydro-4H-benzo[b]thieno[3,2-d]azepin-1-yl cyanide 
• 876048-25-8 12-chloro-5-(4-methylphenylsulphonyl)-6,7-dihydro-5H-benzo[b]pyrimido[5',4':4,5]thieno[3,2-d]azepine 
• 876048-21-4 5-(4-methylphenylsulphonyl)-6,7,11,12-tetrahydro-5H-benzo[b]pyrimido[5',4':4,5]thieno[3,2-d]azepin-12-one 

Relevant academic research and scientific papers

Photoactive NO hybrids with pseudo-zero-order release kinetics for antimicrobial applications

Bacterial infection is a major threat to the health and life of humans due to the development of drug resistance, which is related to biofilm formation. Nitric oxide (NO) has emerged as an important factor in regulating biofilm formation. In order to harness the potential benefits of NO and develop effective antibacterial agents, we designed and synthesized a new class of NO hybrids in which the active scaffold benzothienoazepine was tagged with a nitroso group and further conjugated with quaternary ammoniums or phosphoniums. The temporal release of NO from these hybrids can be achieved by photoactivation. Interestingly, the NO release follows a pseudo-zero-order kinetics, which is easily determined by measuring the fluorescent benzothienoazepine or NO. Compared to the positive control ciprofloxacin, the NO hybrid with triphenyl phosphonium (TPP) exhibited more effective activity against S. aureus biofilm in darkness. Irradiation of the NO hybrid led to higher inhibition against S. aureus biofilm compared to the parental NO hybrid in darkness or the corresponding NO-released product, indicating the combined effect of NO and the NO-released product. Therefore, this new class of NO hybrids includes very promising antimicrobial agents and this work provides a new way for the design of highly effective antimicrobial agents. This journal is

HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

NOVEL BENZO [...] DERIVATIVES AND THEIR MEDICAL USE

One objective of the present invention is to provide a compound having V2 receptor agonist effect. The pharmaceutical composition of this invention uses a compound expressed by the following general formula (I) or its pharmacologically acceptable salt as an active ingredient, wherein, R1 represents the following formula: wherein, A represents a lower alkylene group or the like which may be substituted with a lower alkyl group; R6 represents a hydrogen atom or the like; R7 represents a hydroxyl group, an aromatic heterocyclic group which may be substituted with a lower alkyl group, amine methyl acyl or the like; R2 represents a hydrogen atom or a lower alkyl group; R3 represents a lower alkyl group which may be substituted with 1 to 3 fluorine atoms or a halogen atom; R4 represents 5-membered aromatic monocyclic heterocyclic group, or 5-membered non-aromatic monocyclic heterocyclic group or the like, wherein the heterocyclic group contains at least one nitrogen atom, and may be substituted with a lower alkyl group; R 5 represents a lower alkyl group or a halogen atom or the like.

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions

NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF

A compound having a V2 receptor agonistic activity is provided. Providing a pharmaceutical composition which contains, as an active ingredient, a compound represented by general formula (I) described below: [R1 is formula described below: (A is a lower alkylene group which may be substituted with lower alkyl group; R6 is a hydrogen atom; R7 is a hydroxyl group, an aromatic heterocyclic group which may be substituted with lower alkyl group, carbamoyl group); R2 is a hydrogen atom or lower alkyl group; R3 is lower alkyl group which may be substituted with 1-3 fluorine atoms, or halogen atom; R4 is a five-membered aromatic monocyclic heterocyclic group, five-membered non-aromatic monocyclic heterocyclic group, (provided each heterocyclic groups contain at least one nitrogen atom and may be substituted with a lower alkyl group); and R5 is a lower alkyl group, halogen atom], or pharmacologically acceptable salt thereof.

ANTI-RSV COMPOUNDS

The present invention relates to anti-RSV compounds of Formula (I) and methods for use of the compounds in the treatment and prevention of RSV infection.

Sequential aza-Claisen rearrangement and ring-closing metathesis as a route to 1-benzazepine derivatives

A synthetic strategy based on sequential application of aza-Claisen rearrangement and ring-closing metathesis reaction as key steps has been developed for the synthesis of various 1-benzazepine derivatives of pharmaceutical relevance. Georg Thieme Verlag

VASOPRESSIN V1A ANTAGONISTS

The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.